Lasofoxifene tartrate | CAS#190791-29-8 | estrogen receptor modulator

MedKoo Cat#: 563056 | Name: Lasofoxifene tartrate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lasofoxifene, also known as CP 336156, is a non-steroidal selective estrogen receptor modulator (SERM) for the prevention and treatment of osteoporosis and for the treatment of vaginal atrophy. Lasofoxifene selectively binds to both ERα and ERβ with high affinity. Its IC50 for ERα (1.5 nM) is similar to that of estradiol (4.8 nM) and is at least 10-fold higher than those of tamoxifen and raloxifene.Lasofoxifene is a desmethyl dihydro analog of nafoxidine.

Chemical Structure

Lasofoxifene tartrate

CAS#190791-29-8 (tartrate)

Theoretical Analysis

MedKoo Cat#: 563056

Name: Lasofoxifene tartrate

CAS#: 190791-29-8 (tartrate)

Chemical Formula: C32H37NO8

Exact Mass: 563.2519

Molecular Weight: 563.65

Elemental Analysis: Chemical Formula: C32H37NO8 Exact Mass: 563.2519 Molecular Weight: 563.6470 Elemental Analysis: C, 68.19; H, 6.62; N, 2.49; O, 22.71

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 Weeks
50mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

180916-16-9 (free base) 190791-29-8 (tartrate)

Synonym

Lasofoxifene tartrate; Fablyn; CP-336156; CP 336156; CP336156;

IUPAC/Chemical Name

(5R,6S)-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol

InChi Key

INEHJXCWEVNEDZ-LUDNRVPPSA-N

InChi Code

InChI=1S/C28H31NO2.C4H6O6/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29;5-1(3(7)8)2(6)4(9)10/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2;1-2,5-6H,(H,7,8)(H,9,10)/t26-,28+;1-,2-/m10/s1

SMILES Code

OC1=CC=C2C(CC[C@]([C@]2([H])C3=CC=C(OCCN4CCCC4)C=C3)([H])C5=CC=CC=C5)=C1.O[C@@](C(O)=O)([H])[C@@](O)([H])C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Lasofoxifene (CP-336156) tartrate is an orally active and selective estrogen receptor modulator (SERM).

In vitro activity:

TBD

In vivo activity:

As a monotherapy, lasofoxifene was more effective than fulvestrant at inhibiting primary tumor growth and reducing metastases in mouse model. The results demonstrate the potential of using lasofoxifene as an effective therapy for women with advanced or metastatic ER+ breast cancers expressing the most common constitutively active ERα mutations.

	Solvent	mg/mL	mM
Solubility
	DMF	1.0	1.77
	DMSO	61.4	109.01
	DMSO:PBS (pH 7.2) (1:2)	0.3	0.44

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 563.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Lainé M, Fanning SW, Chang YF, Green B, Greene ME, Komm B, Kurleto JD, Phung L, Greene GL. Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer. Breast Cancer Res. 2021 May 12;23(1):54. doi: 10.1186/s13058-021-01431-w. PMID: 33980285; PMCID: PMC8117302. 2. Andersson A, Bernardi AI, Stubelius A, Nurkkala-Karlsson M, Ohlsson C, Carlsten H, Islander U. Selective oestrogen receptor modulators lasofoxifene and bazedoxifene inhibit joint inflammation and osteoporosis in ovariectomised mice with collagen-induced arthritis. Rheumatology (Oxford). 2016 Mar;55(3):553-63. doi: 10.1093/rheumatology/kev355. Epub 2015 Sep 30. PMID: 26424839; PMCID: PMC4746431.

In vitro protocol:

TBD

In vivo protocol:

1: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Sep;30(7):543-88. PubMed PMID: 18985183. 2: Prakash C, Johnson KA, Schroeder CM, Potchoiba MJ. Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys. Drug Metab Dispos. 2008 Sep;36(9):1753-69. doi: 10.1124/dmd.108.021808. Epub 2008 May 30. PubMed PMID: 18515329. 3: Space JS, Opio AM, Nickerson B, Jiang H, Dumont M, Berry M. Validation of a dissolution method with HPLC analysis for lasofoxifene tartrate low dose tablets. J Pharm Biomed Anal. 2007 Sep 3;44(5):1064-71. Epub 2007 May 3. PubMed PMID: 17560750. 4: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Sep;28(7):451-95. Review. PubMed PMID: 17003851. 5: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Jul-Aug;28(6):379-412. PubMed PMID: 16894408. 6: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2006 Jan-Feb;28(1):31-63. PubMed PMID: 16541195. 7: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Sep;27(7):505-22. PubMed PMID: 16258596. 8: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jul-Aug;27(6):411-61. PubMed PMID: 16179960. 9: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005 Jan-Feb;27(1):49-77. PubMed PMID: 15834459. 10: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Jul-Aug;25(6):483-506. PubMed PMID: 12949633. 11: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):615-43. PubMed PMID: 12616707. 12: Ke HZ, Paralkar VM, Grasser WA, Crawford DT, Qi H, Simmons HA, Pirie CM, Chidsey-Frink KL, Owen TA, Smock SL, Chen HK, Jee WS, Cameron KO, Rosati RL, Brown TA, Dasilva-Jardine P, Thompson DD. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology. 1998 Apr;139(4):2068-76. PubMed PMID: 9528995.